---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-044036"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2023-08-23T23:59:59+00:00"
generated_at: "2026-06-11T04:54:28.866379+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology completes all-stock acquisition of Apexigen for ~$10.7M

## Summary
- Pyxis issued ~4.3M shares (exchange ratio 0.1725) so Apexigen holders own ~10% of combined co.
- Acquisition adds clinically validated APXiMAB antibody-discovery platform and Phase 2 CD40 agonist sotigalimab (now PYX-107).
- Combined co. positions for next-gen ADC creation; cash runway extended into 1H 2025.
- Jakob Dupont, former Apexigen director, appointed to Pyxis board as independent Class III director.
- Development strategy and timelines for PYX-107 to be shared in 4Q23.

## SEC filing metadata
- accession: 0000950170-23-044036
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2023-08-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017023044036/0000950170-23-044036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017023044036/pyxs-20230823.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-044036
- JSON: https://secwatch.observer/filing/0000950170-23-044036.json
- Plain text: https://secwatch.observer/filing/0000950170-23-044036.txt

## Key facts
- Executive change
  Jakob Dupont was appointed as Director at Pyxis Oncology, Inc..
  - Action: appointed
  - Role: Director
  source text: On August 23, 2023, effective as of the Effective Time, Jakob Dupont, M.D., a former director of Apexigen, was appointed to the Board as a Class III director and his term will expire at the annual meeting of stockholders to be held in 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782223/000095017023044036/0000950170-23-044036-index.htm
- M&A Transactions
  Pyxis Oncology, Inc. completed an acquisition involving Apexigen, Inc. for all-stock transaction valued at approximately $10.7 million (closed 2023-08-23).
  - Action: acquisition
  - Counterparty: Apexigen, Inc.
  - Consideration: all-stock transaction valued at approximately $10.7 million
  - Closing: 2023-08-23
  source text: clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology, in an all-stock transaction valued at approximately $10.7 million. The combined company is positioned at the forefront of ADC innovation with a platform that now includes four key components: novel humanized antibody generation capabilities, an
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782223/000095017023044036/0000950170-23-044036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.